Abstract | OBJECTIVES: METHODS: A disproportionality analysis, adjusted for age and sex, was conducted for VAERS reports from individuals who were vaccinated at the age of 18 years or over, between January 2010 and April 2021. RESULTS: The analysis revealed that the adverse events following immunization (AEFI) of facial nerve palsy, after administration of COVID-19 mRNA vaccines, was significantly highly reported, both for BNT162b2 (reporting odds ratio [ROR] 1.84; 95% confidence interval [CI] 1.65-2.06) and mRNA-1273 (ROR 1.54; 95% CI 1.39-1.70). These levels were comparable to that following influenza vaccination reported before the COVID-19 pandemic (ROR 2.04; 95% CI 1.76-2.36). CONCLUSIONS: Our pharmacovigilance study results suggest that the incidence of facial nerve palsy as a non-serious AEFI may be lower than, or equivalent to, that for influenza vaccines. This information might be of value in the context of promoting worldwide vaccination, but needs to be validated in future observational studies.
|
Authors | Kenichiro Sato, Tatsuo Mano, Yoshiki Niimi, Tatsushi Toda, Atsushi Iwata, Takeshi Iwatsubo |
Journal | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
(Int J Infect Dis)
Vol. 111
Pg. 310-312
(Oct 2021)
ISSN: 1878-3511 [Electronic] Canada |
PMID | 34492394
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- COVID-19 Vaccines
- Influenza Vaccines
- RNA, Messenger
- BNT162 Vaccine
|
Topics |
- Adolescent
- Adult
- Adverse Drug Reaction Reporting Systems
- BNT162 Vaccine
- Bell Palsy
(epidemiology)
- COVID-19
- COVID-19 Vaccines
(adverse effects)
- Facial Nerve
- Humans
- Influenza Vaccines
(adverse effects)
- Pandemics
- Paralysis
- RNA, Messenger
(genetics)
- SARS-CoV-2
- Young Adult
|